BridgeBio Pharma: ATTRibute-CM Study Fails To Meet Primary Endpoint At Month 12

BridgeBio Pharma, Inc. (BBIO) reported topline results from month 12 of ATTRibute-CM, an ongoing phase 3 study investigating acoramidis for the treatment of symptomatic transthyretin amyloid cardiomyopathy. ATTRibute-CM did not meet its primary endpoint at month 12. The company noted that ATTRibute-CM independent data monitoring committee recommended continuing the study based on unblinded data reviews.

"This result is disappointing and baffling. I am, along with many others, searching for answers regarding the 6MWD," said Neil Kumar, founder and CEO of BridgeBio.

BridgeBio said it is well-capitalized through the completion of ATTRibute-CM and remains on track to deliver on additional catalysts in 2022 and 2023.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Cargill, Inc., a privately held food company, is recalling certain chocolate products containing recalled Jif peanut butter due to the potential for salmonella contamination, the U.S. Food and Drug Administration said. The recall involves 795, 8-ounce boxes of Wilbur brand products, such as Milk and Dark Chocolate Covered Peanut Butter Ritz Crackers, Peanut Butter Meltaways... The U.S. Food and Drug Administration approved Regeneron Pharmaceuticals, Inc.'s Dupixent (dupilumab) to treat eosinophilic esophagitis or EoE, a chronic immune disorder. It is the first FDA approval to treat EoE in adults and pediatric patients 12 years and older weighing at least 40 kilograms. Food products maker J. M. Smucker Co. has recalled select Jif peanut butter products sold in the United States due to potential Salmonella contamination, the U.S. Food and Drug Administration said. The recall involves various creamy, crunchy, natural, no added sugar, and reduced fat peanut butter, among others with lot codes 1274425 - 2140425.
Follow RTT